Patients
The study was designed as a prospective population-based multicentre study. Consecutive Danish patients with primary adenocarcinoma of the colon and rectum diagnosed before the age of 50, with official address in a participating county, were invited to participate. Written informed consent was required to include a patient, and the study was approved by the local ethical committee. 4 Danish counties (population 1.4 million, 26% of the Danish population) were successively included in the study from November 1995 to October 1998. (County of Aarhus was included November 1995, County of Ribe -August 1996, County of Ringkoebing -March 1997 and County of Viborg was included August 1997.) All Danish CRC patients are diagnosed and treated in the public health care system, and lists of all CRC patients from the Institutes of Pathology covering the area were checked regularly to ensure that no CRC patients were missed.
Family history
The surgeons filled in a questionnaire covering malignancy and age at time of diagnosis among family members, and the study group interviewed all patients about sex, current age or age at time of death for all first and second degree relatives. Hospital files, death certificates or information from the Danish Cancer Registry were requested on each family member with a possible HNPCC related cancer.
Statistical methods
For each family the probability of meeting the Amsterdam Criteria I by chance was calculated using a specific FORTRAN program developed by the study group. The calculations were based on the age-and sex-specific incidence data from the Danish Cancer Registry for the year 1990 (Storm et al, 1994) .
The Amsterdam criteria I, can be met through 7 different paths ( Figure 1 ). Path 1 includes the patient, the parents and the grandparents. Path 2 includes the patient, the parents and the patient's children. It is clear that 5 additional paths exist, #3 to #7 in Figure 1 .
The probability that a young colorectal cancer patient's family meets the Amsterdam criteria I by chance depends on the number of first and second degree relatives, their sex and current age or age at death and on the cumulative incidence rate of colorectal cancer in the background population.
If a patient is able to supply the above information for his/her parents and grandparents, the Amsterdam criteria I can be met in 4 different ways through path #1 (patient + patient's father + patient's father's father or father's mother or patient + patient's mother + patient's mother's father or mother). Information about any children generates new combinations through path #2. These principles continue through path #3-#7. The probabilities from the various paths are combined to yield the family's probability of meeting the Amsterdam criteria I.
RESULTS

Families meeting the Amsterdam criteria I
Among 1514 consecutive CRC patients, 87 (5.7%) were diagnosed before the age of 50. 77 patients (88.5%) were interviewed, and 4 families met the strict Amsterdam criteria I. Another 2 families did not meet the strict criteria due to lack of a verified diagnosis in a third family member. In one family, the third tumour was located at the splenic flexure detected on X-ray examination. Histology from metastasis showed adenocarcinoma. In another family the third family member had a big abdominal tumour and blood in the stool. Histology showed mucinous adenocarcinoma consistent with colorectal cancer. Hence for all practical purposes 6 families (6/77 = 7.8%) met the Amsterdam criteria I. By including the 2 family members described above, we observed 24 CRC cases in the 6 families, and all cases were histologically verified.
Probability calculations
77 patients (77/87 = 88.5%) supplied information about current age or age at the time of death and sex among 1407 first and second degree relatives (an average of 18.3 members per family).
Every family's probability of meeting the Amsterdam criteria I by chance was calculated. The 77 families' risk of sporadically meeting the Amsterdam criteria I ranged from 0.0% to 7.1%, the average chance being 1.1%. 13 of the 77 families (17%) had a more than 2% risk of meeting the Amsterdam criteria I by coincidence.
In this sample of 77 families the estimated chance of sporadic fulfilment of the Amsterdam criteria I corresponds to an expectation of 0.83 family. The chances of finding at least 1, 2 or 3 Amsterdam I positive families follow a binomial distribution and these are 56.7%, 20.2% and 5.1% respectively. The probabilities of finding 4, 5 or 6 positive families are 1.0%, 0.2% and 0.02%, respectively. In this sample of 77 families, the median expected number of families meeting the Amsterdam criteria I by coincidence is 1 (95% confidence limits 0-3).
DISCUSSION
In this study the chance of a family meeting the Amsterdam criteria I by coincidence, has been quantified for the first time on real families. 6 out of 77 families (7.8%) met the Amsterdam criteria I. We estimated a 0.02% probability of finding 6 or more families due to coincidental clustering in this material, so it is very unlikely that all 6 families are coincidental. Pathogenic mutations in the genes hMLH1 or hMSH2 are detected in approximately 50% of the families that meet the Amsterdam criteria I, and in 8-28% of suspected HNPCC families depending on which criteria of suspicion that are used (Buerstedde et al, 1995; Moslein et al, 1996; Viel et al, 1997; Wijnen et al, 1998; Park et al, 1999 ). Therefore we would not expect that all families would meet the criteria by coincidence.
Our calculations show, that when 77 young CRC patients are interviewed, there is a 56.7% chance of finding at least 1 family meeting the criteria. There is a 20.2% risk of finding 2 or more families by coincidence, and a 5.1% risk of finding 3 or more families that meet the criteria by coincidence. Hence, the most likely outcome is, that 1 out of our 6 families (17%), is the result of coincidental aggregation of CRC among family members.
The 6 families who met the Amsterdam criteria I were screened for hMLH1/hMSH2 mutations by SSCP, HD and PTT (data not shown). We have previously shown that the combination of using SSCP and HD are highly sensitive for the detection of hMLH1/hMSH2 mutations (Wikman et al, 2000) . We detected mutations in 2 out of the 6 families, leaving us with 4 unexplained families. Therefore, the risk of meeting the Amsterdam criteria I by chance in mutation negative families is more likely 1 in 4 (25%) than the 1 in 6 (17%) risk that we have demonstrated on the Amsterdam criteria I positive families where mutational status is not taken into account.
The calculations are based on the assumption of a low proportion of hereditary CRC cases among the total number of CRC cases in Denmark and that environmental exposures and dietary habits are similar in Danish families.
We recommended all 6 families to follow the surveillance programme proposed by ICG-HNPCC. It is impossible to distinguish between HNPCC families and families who meet the criteria by coincidence, unless a pathogenic mutation has been detected.
Our results show that the majority of families of young CRC patients, who meet the Amsterdam criteria I are likely to be due to a genetic predisposition, but a considerable fraction of the families can be explained by chance aggregation of CRC in family members.
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